



PACIFIC RESEARCH NETWORK

3003 Fourth Avenue, San Diego, CA 92103 * (619) 294-4302 Ph. (619) 294-4867 Fax

THOMAS J. REILLY, M.D., MPH

EDUCATION

1993 MPH: San Diego State University, San Diego, California
1983 Post Graduate: Oakland Naval Hospital, Oakland, California
1982 Medical: Georgetown University School of Medicine, Washington, DC
1978 BS: Vanderbilt University, School of Engineering, Nashville, Tennessee

MEDICAL EXPERIENCE

2004 – Present Staff Physician, Pacific Research Network, San Diego, California
2004 – Present Chairman, Aspire Institutional Review Board, San Diego, California
1998 – Present Volunteer Preceptor, University of California San Diego School of Medicine
San Diego, California
2005 – Present Community Member, Institutional Bio-safety Committee, Kaiser Permanente
Southern California
2001 – 2004 Institutional Review Board Member, Vice Chair, Medical Consultant,
Biomedical Research Institute of America, San Diego, California
1994 – 1995 Medical Officer, America's Cup Challenger Series
1991 – 1992 Medical Officer, America's Cup Challenger Series
1990 – 2000 Associate Medical Director, Occupational Medicine, Sharp-Rees Stealy Medical
Group, San Diego, California
1988 – 1989 Staff Physician, Sharp-Rees Stealy Medical Group, San Diego, California
1986 - 1987 Officer in Charge, Flight Line Clinic, U.S. Navy, Moffett Field, California
1984 – 1987 Flight Surgeon, U.S. Navy
1986 – 1987 Regional Naval Medical Clinic Executive Policy Committee, U.S. Navy
1984 – 1985 Special Board of Flight Surgeons, U.S. Navy
1983 Emergency Room Physician, Oakland Naval Hospital, Oakland, California

CERTIFICATION AND LICENSURE

Board Certification in Occupational and Environmental Medicine

LICENSURE:

State of California
License Number: G 51288
Expiration Date: January 31, 2009

CLINICAL RESEARCH EXPERIENCE

1. A Randomized, Double-Blind, Placebo-Controlled Trial of XXXX to Attenuate the Progression of Alzheimer's Disease. (00026)
2. A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of XXXX in Patients with Mild-To-Moderate Dementia of the Alzheimer's Type. (202793)
3. A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Safety and Efficacy of XXXX 25 mg in Slowing the Progression of Alzheimer's Disease. (202531)
4. A Double-Blind, Phase II, Safety and Efficacy Evaluation of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (203096PRN)
5. An Evaluation of the Long-Term Safety and Efficacy of XXXX in Patients with Moderate to Severe Dementia of the Alzheimer's Type. (202891)
6. A Long-Term Extension Study Evaluating the Safety and Tolerability of BID and QD Administration of XXXX in Patients with Mild to Moderate Dementia of the Alzheimer's Type. (3811x1)
7. A Phase III Study of the Efficacy and Safety of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (203077PRN)
8. A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Safety and Efficacy of XXXX in Patients with Restless Legs Syndrome. (203812PRN)
9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Efficacy and Safety of XXXX in Subjects with Mild to Moderate Alzheimer's Disease. (00012)
10. A One Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of XXXX in Subjects with Mild Cognitive Impairment. (202493)
11. A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of XXXX at Dosages up to 16mg/day in Adults with Generalized Anxiety Disorder. (202976)
12. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX (150 and 250 mg/day) as Treatment for Adults with Residual Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome. (203233)
13. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX (150 and 250 mg/day) as Treatment for Adults with Excessive Sleepiness Associated with Narcolepsy. (203231)
14. A 12-Month, Open-Label, Flexible-Dosage (100-2500 mg/day) Extension Study of the Safety and Efficacy of XXXX in the Treatment of Patients with Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder. (203903)
15. An Analysis of Mortality in Subjects who Participated in Three Studies of XXXX in Mild Cognitive Impairment. (00006)

16. A Study To Define the Non-Restorative Sleep Population. (00010)
17. A 6-Month Safety Follow-up Study to Select Patients Previously Enrolled and Randomized to XXXX in Studies XXXX, XXXX, or XXXX. (00028)
18. Evaluation of the Long-Term Efficacy and Safety of XXXX 12.5 mg Compared to Placebo, When Both are Administered Over a Long-Term Period “as needed”, in Patients with Chronic Primary Insomnia. (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase IIIb Clinical Study). (00007)
19. A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of XXXX in Patients with Mild to Moderate Alzheimer’s Disease. (00025)
20. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Once Daily XXXX in Patients with Restless Legs Syndrome. (00036)
21. A Double-Blind, Placebo-Controlled Study of XXXX for the Treatment of Mild-To-Moderate Alzheimer’s Disease. (00065)
22. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety and Tolerability of XXXX in Patients with Generalized Anxiety Disorder. (00054)
23. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of XXXX in Subjects with Idiopathic Restless Legs Syndrome. (00046)
24. A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study In Patients with Mild to Moderate Dementia of the Alzheimer’s Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered XXXX. (00063)
25. The Efficacy of XXXX 3 mg as Adjunctive Therapy in Subjects with Insomnia Related to Generalized Anxiety Disorder. (00057)
26. A 12 Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of XXXX (Extended Release) in Patients with Restless Legs Syndrome. (00059)
27. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Polysomnographic Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXXX in Primary Insomnia Patients with Sleep Maintenance Difficulties. (00047)
28. Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Daily Treatment with XXXX on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer’s Type. (00023)
29. A Randomized, Double-Blind, Placebo- and Active-Controlled, Multicenter, Proof of Concept Trial of XXXX in Subjects with Nonrestorative Sleep. (00095)
30. Efficacy and Safety of XXXX 5mg/Day on Sleep Maintenance Insomnia: A 6-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. (00103)

31. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of a Single Oral Dose of XXXX (20, 50, and 100 mg) and Matching Placebo in Healthy Male and Female Subjects with Induced Transient Insomnia. (00107)
32. A Randomized, Double-Blind Comparison of 5 mg of XXXX, 15 mg of XXXX, and Placebo in the Treatment of Patients with Primary Insomnia. (00076)
33. A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Effects of the XXXX in Patients with Insomnia. (00077)
34. A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effects of XXXX (2.5, 10 and 30 mg) on Polysomnographic Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Elderly and Nonelderly Subjects with Primary Insomnia. (00088)
35. A 28-Week Open-Label Extension Study Evaluating the Safety and Tolerability of XXXX (E2020) in Subjects with Mild Cognitive Impairment. (00105)
36. An Open-Label Extension Trial to Investigate the Safety and Tolerability of Long-Term Treatment with Transdermal XXXX in Subjects with Idiopathic Restless Legs Syndrome. (00093)
37. Open-Label Study of the Effect of Daily Treatment with XXXX in Subjects with Dementia of the Alzheimer's Type. (00139)
38. An 8-Week, Randomized, Double-Blind, Fixed-Dosage, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy, Safety and Tolerability of XXXX 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-Week, Open-Label Extension (CAGO178A2302E). (00125)
39. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXX in Patients with Restless Legs Syndrome. (00056)
40. An Open-Label, 52-Week Extension Study Assessing XXXX Safety and Efficacy in Patients with Restless Legs Syndrome. (00114)
41. A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XXXX in Patients with Restless Legs Syndrome. (00141)
42. Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Daily Treatment with XXXX on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's Type. (00128)
43. A Multi-Center, Double-Blind, Parallel-Group, Fixed-Dose, 4-Arm, Placebo and XXXX Controlled 8-Week Efficacy Study of 2 Oral Doses of XXXX (175 mg or 350 mg, bid) in Adult Outpatients with Major Depressive Disorder. (00022)
44. A 54-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effects of XXXX (Extended Release Tablets) as Adjunctive Therapy to

- Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE ϵ 4-Stratified Subjects with Mild to Moderate Alzheimer's Disease (REFLECT-3). (00123)
45. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of XXXX on Cognitive Functions in the Elderly. (00058)
 46. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX in Migraine Prophylaxis. (00082)
 47. A 52-Week, Open-Label Study to Assess the Long-Term Safety of XXXX Extended Release (XR) in Patients with Restless Legs Syndrome (RLS). (00075)
 48. An Open-Label Extension of the Phase III Study CL-758007 with XXXX in Patients with Alzheimer's Disease. (00107)
 49. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Demonstrate the Subjective Treatment Effects of XXXX on Sleep Using a Post Sleep Questionnaire-Interactive Voice Response System (PSQ-IVRS) in an "At-Home Setting" in an Adult Population with Chronic Insomnia. (00145)
 50. Effect of XXXX in Slowing the Progression of Alzheimer's Disease. (00134)
 51. A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of XXXX 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects. (00090)